Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia.

Virginio SalviCristina AppignanesiBrodinela MarpepaLaura OrsoliniUmberto Volpe

Published in: Neuropsychopharmacology reports (2022)

Aripiprazole LAI showed good efficacy and tolerability in an adolescent with schizophrenia. The two-injection start regimen was a safe and effective option.

Keyphrases

bipolar disorder
young adults
mental health
ultrasound guided
open label
childhood cancer
randomized controlled trial
clinical trial
double blind